InMed Pharmaceuticals Inc...

3.13
-0.04 (-1.26%)
At close: Feb 10, 2025, 3:59 PM
3.12
-0.48%
After-hours Feb 10, 2025, 07:08 PM EST
undefined%
Bid 3
Market Cap 2.27M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 230.4
PE Ratio (ttm) 0.01
Forward PE n/a
Analyst n/a
Ask 3.3
Volume 28,112
Avg. Volume (20D) 496,031
Open 3.13
Previous Close 3.17
Day's Range 3.08 - 3.20
52-Week Range 2.42 - 15.70
Beta undefined

About INM

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it en...

Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2014
Employees 13
Stock Exchange NASDAQ
Ticker Symbol INM
3 weeks ago
+2.02%
InMed Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription
2 months ago
-15.75%
InMed Pharmaceuticals shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.